Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Macrophages play a pivotal role in atherosclerotic plaque development. Recent evidence has suggested the glucagon-like peptide-1 receptor (GLP-1R) agonist, liraglutide, can attenuate pro-inflammatory responses in macrophages. We hypothesized that liraglutide could limit atherosclerosis progression in vivo via modulation of the inflammatory response. Human THP-1 macrophages and bone marrow-derived macrophages, from both wild-type C57BL/6 (WT) and apolipoprotein E null mice (ApoE −/− ) were used to investigate the effect of liraglutide on the inflammatory response in vitro. In parallel, ApoE −/− mice were fed a high-fat (60% calories from fat) high-cholesterol (1%) diet for 8 weeks to induce atherosclerotic disease progression with/without daily 300 μg/kg liraglutide administration for the final 6 weeks. Macrophages were analysed for MΦ1 and MΦ2 macrophage markers by Western blotting, RT-qPCR, ELISA and flow cytometry. Atherosclerotic lesions in aortae from ApoE −/− mice were analysed by en face staining and monocyte and macrophage populations from bone marrow derived cells analysed by flow cytometry. Liraglutide decreased atherosclerotic lesion formation in ApoE −/− mice coincident with a reduction in pro-inflammatory and increased anti-inflammatory monocyte/macrophage populations in vivo. Liraglutide decreased IL-1beta in MΦ0 THP-1 macrophages and bone marrow-derived macrophages from WT mice and induced a significant increase in the MΦ2 surface marker mannose receptor in both MΦ0 and MΦ2 macrophages. Significant reduction in total lesion development was found with once daily 300 μg/kg liraglutide treatment in ApoE −/− mice. Interestingly, liraglutide inhibited disease progression at the iliac bifurcation suggesting that it retards the initiation and development of disease. These results corresponded to attenuated MΦ1 markers (CCR7, IL-6 and TNF-alpha), augmented MΦ2 cell markers (Arg-1, IL-10 and CD163) and finally decreased MΦ1-like monocytes and macrophages from bone marrow-derived cells. This data supports a therapeutic role for liraglutide as an atheroprotective agent via modulating macrophage cell fate towards MΦ2 pro-resolving macrophages.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 2×
“The results of the LEADER trial showed that diabetic patients had a 13% reduction in risk of CV deaths following liraglutide administration [15].”
BackgroundResultInfluentialStamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063
Macrophages in the Pathogenesis of Atherosclerosis
Moore, K. J., & Tabas, I. (2011) · Cell · doi:10.1016/j.cell.2011.04.005 · Cited by 2,669
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409 · cited 1×
“Furthermore, the Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) trial showed that lixisenatide confers a CV benefit rather than an absence of adverse effects [17].”
BackgroundDiabetes and Glucose Tolerance as Risk Factors for Cardiovascular Disease: The Framingham Study
Kannel, W. B., & McGee, D. L. (1979) · Diabetes Care · doi:10.2337/diacare.2.2.120 · Cited by 1,203 · cited 1×
“Framingham data with 20 year follow-up revealed that patients with DM had a 2–3-fold increase in atherosclerotic disease [2].”
MethodSabat, R., Grütz, G., Warszawska, K., Kirsch, S., Witte, E., Wolk, K., & Geginat, J. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2010.09.002 · Cited by 977 · cited 1×
“Polarizing MΦ1 macrophages requires LPS which in turn activates NF-κB which is known to activate STAT3 and IL-10 signalling [27].”
Backgroundle Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C. W., Van Gaal, L., Ortiz, R. V., Wilding, J. P. H., Skjøth, T. V., Manning, L. S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30069-7 · Cited by 850 · cited 1×
“8 mg/kg, as opposed to 3 mg/kg used to treat obesity [37].”
BackgroundArakawa, M., Mita, T., Azuma, K., Ebato, C., Goto, H., Nomiyama, T., Fujitani, Y., Hirose, T., Kawamori, R., & Watada, H. (2010) · Diabetes · doi:10.2337/db09-1694 · Cited by 548
Macrophage plasticity in experimental atherosclerosis
Khallou-Laschet, J., Varthaman, A., Fornasa, G., Compain, C., Gaston, A.-T., Clement, M., Dussiot, M., Levillain, O., Graff-Dubois, S., Nicoletti, A., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008852 · Cited by 517 · cited 1×
“However, it has been proposed that atherosclerosis-associated inflammation may not primarily be due to a skewing of the MΦ1:MΦ2 ratio, but also loss of anti-inflammatory MΦ2 macrophages resulting in impaired resolution of inflammation [8, 12].”
BackgroundMacrophage Diversity and Polarization in Atherosclerosis: A Question of Balance
Mantovani, A., Garlanda, C., & Locati, M. (2009) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.180497 · Cited by 426
Cited by
Macrophage polarization: an important role in inflammatory diseases
Luo, M., Zhao, F., Cheng, H., Su, M., & Wang, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1352946 · Cited by 468
GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
Zhao, X., Wang, M., Wen, Z., Lu, Z., Cui, L., Fu, C., Xue, H., Liu, Y., & Zhang, Y. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.721135 · Cited by 463
“Liraglutide was found to directly affect the formation of atherosclerotic lesions by tilting the macrophage population to the M-F-2 phenotype that is conducive to decomposition (127).”
BackgroundThe anti-inflammatory and immunological properties of GLP-1 Receptor Agonists
Bendotti, G., Montefusco, L., Lunati, M. E., Usuelli, V., Pastore, I., Lazzaroni, E., Assi, E., Seelam, A. J., El Essawy, B., Jang, J., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106320 · Cited by 406
GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
Ma, X., Liu, Z., Ilyas, I., Little, P. J., Kamato, D., Sahebka, A., Chen, Z., Luo, S., Zheng, X., Weng, J., et al. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59965 · Cited by 299
Simms-Williams, N., Treves, N., Yin, H., Lu, S., Yu, O., Pradhan, R., Renoux, C., Suissa, S., & Azoulay, L. (2024) · BMJ · doi:10.1136/bmj-2023-078242 · Cited by 151
“35 The anti-inflammatory and anti-oxidative effects of GLP-1 receptor agonists may also result in decreased albuminuria, reduced mesangial expansion, and improved glomerular hyperfiltration and endothelial function, explaining their renoprotective effects.”
Background
Metadata
- Authors
- Bruen, R., Curley, S., Kajani, S., Crean, D., O’Reilly, M. E., Lucitt, M. B., Godson, C. G., McGillicuddy, F. C., & Belton, O.
- Venue
- Cardiovascular Diabetology
- Published
- 2017-11-06
- Volume
- 16
- Issue
- 1
- Pages
- 143-143
- ISSN
- 1475-2840 (ISSN-L)
- OpenAlex
- W2767936163
- Cited by
- 81
- References
- 20
- FWCI
- 2.72
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis. https://app.cochat.ai/papers/10.1186/s12933-017-0626-3
- The paper
- Bruen, R., Curley, S., Kajani, S., Crean, D., O’Reilly, M. E., Lucitt, M. B., Godson, C. G., McGillicuddy, F. C., & Belton, O. (2017). Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis. Cardiovascular Diabetology. https://doi.org/10.1186/s12933-017-0626-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.